The Cigna Group
CI
$279.05
-2.99%
The Cigna Group is a global health services company that provides health insurance and pharmacy benefit management (PBM) services, primarily operating in the U.S. Its core offerings include employer-sponsored health plans and the Evernorth PBM platform, which was significantly expanded through the 2018 Express Scripts merger. Cigna is a major player in the healthcare sector, competing with other large insurers and PBMs, and is distinguished by its scale in PBM contracts, including a major Department of Defense contract and a recent multiyear deal with Centene. The current investor narrative centers on Cigna's strategic pivot, as it recently raised its full-year outlook while announcing an exit from the individual exchange market and a strategic review of its eviCore business, signaling a focus on core operations and potential portfolio reshaping. This has introduced both optimism about improved profitability and concerns about execution risk during the transition.…
CI
The Cigna Group
$279.05
Related headlines
Investment Opinion: Should I buy CI Today?
Cigna is rated a Buy based on its deep value, with a forward P/E of 8.33x and a PEG of 0.15, well below industry averages. The average analyst target of $340.92 implies 22.2% upside, and the consensus leans bullish. The company's revenue growth of 4.57% YoY, strong free cash flow of $7.66 billion, and improving operating margins (3.32% in Q1 2026) support the thesis. However, the rating would be downgraded to Hold if the strategic review leads to disruptive divestitures or if revenue growth decelerates below 3%. Conversely, an upgrade to Strong Buy would be warranted if the forward P/E compresses below 7x or if the company announces a large share buyback. Overall, Cigna is undervalued relative to its history and peers, offering a favorable risk/reward.
Sign up to view all
CI 12-Month Price Forecast
The AI assessment leans bullish due to the compelling valuation metrics and positive analyst sentiment. However, confidence is medium because the strategic review introduces execution risk, and the stock's underperformance relative to the market suggests lingering skepticism. The key factor is whether management can deliver on its raised guidance and successfully reshape the portfolio. If the company demonstrates improved margins and revenue acceleration, the stance would be upgraded to high confidence. Conversely, any signs of operational missteps or margin compression would warrant a downgrade to neutral.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on The Cigna Group's 12-month outlook, with a consensus price target around $343.38 and implied upside of +23.1% versus the current price.
Average Target
$343.38
0 analysts
Implied Upside
+23.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$290 - $400
Analyst target range
Cigna is covered by 24 analysts, with a consensus recommendation that leans bullish, as evidenced by recent actions from firms like Bernstein (Outperform), Mizuho (Outperform), and UBS (Buy), though there have been some downgrades, such as Barclays moving to Equal Weight and Deutsche Bank to Hold. The average target price is $340.92, implying a 22.2% upside from the current price of $279.05, while the low target of $290.00 still suggests a 3.9% upside, and the high target of $400.00 implies a 43.3% upside. The wide range between the low and high targets (38% spread) indicates significant uncertainty about the company's future, likely due to the ongoing strategic review and potential divestitures, but the overall positive sentiment and substantial upside potential make Cigna an attractive investment for those willing to accept the execution risk.
Bulls vs Bears: CI Investment Factors
Cigna presents a classic value opportunity with a forward P/E of 8.33x and a PEG of 0.15, suggesting the market is pricing in substantial earnings growth. The company's steady revenue growth, strong free cash flow, and strategic focus on core operations support the bull case. However, the stock's underperformance relative to the S&P 500, execution risks from the strategic review, and thin margins in its dominant PBM segment temper enthusiasm. The most important tension is whether the strategic pivot will successfully improve profitability and justify the low valuation, or whether execution missteps will erode investor confidence. Currently, the bull case has stronger evidence given the deep value and analyst upside, but the wide target range highlights the uncertainty.
Bullish
- Deep Value with PEG of 0.15: Cigna trades at a forward P/E of 8.33x, a 32.5% discount to its trailing P/E of 12.34x, implying the market expects significant earnings growth. The PEG ratio of 0.15x is exceptionally low, suggesting the stock is undervalued relative to its growth prospects, making it a compelling value proposition.
- Analyst Consensus Bullish with 22% Upside: With 24 analysts covering the stock, the average price target is $340.92, implying a 22.2% upside from the current price of $279.05. Recent actions from Bernstein, Mizuho, and UBS include Outperform and Buy ratings, reflecting positive sentiment despite some downgrades.
- Steady Revenue Growth and Strong Cash Flow: Q1 2026 revenue grew 4.57% YoY to $68.49 billion, with consistent mid-single-digit growth over recent quarters. The company generated $7.66 billion in trailing twelve-month free cash flow, providing ample liquidity for strategic initiatives and shareholder returns.
- Strategic Pivot Enhances Profitability Focus: Cigna raised its full-year outlook while announcing an exit from the individual exchange market and a strategic review of eviCore. This focus on core operations (Evernorth PBM and employer health plans) could improve margins and reduce volatility, as evidenced by the raised guidance.
Bearish
- Underperformance vs. S&P 500: Over the past year, Cigna's stock gained only 4.36% compared to the S&P 500's 18.19%, underperforming by 13.8 percentage points. This relative weakness may persist if the market continues to favor growth stocks over value-oriented healthcare names.
- Execution Risk from Strategic Review: The exit from the individual exchange market and the strategic review of eviCore introduce uncertainty. Divestitures or operational changes could disrupt earnings and distract management, as highlighted by the recent news of raised outlook but flagged execution risk.
- Thin Gross Margins and High Revenue Concentration: Cigna's gross margin is only 9.45%, reflecting the low-margin nature of its PBM business, which contributes $58.44 billion of Q1 2026 revenue (85% of total). This concentration makes the company sensitive to PBM pricing pressures and contract renegotiations.
- Elevated Debt Levels: With a debt-to-equity ratio of 0.75, Cigna carries significant leverage. While manageable, high debt could limit financial flexibility and increase interest expense, which was $357 million in Q1 2026, especially if rates remain elevated.
CI Technical Analysis
Cigna's stock has been in a broad recovery phase over the past year, with a 1-year price change of +4.36%, though it has underperformed the S&P 500's +18.19% gain over the same period. The current price of $279.05 sits at 39.5% of the 52-week range (between the low of $239.51 and high of $315.47), indicating the stock is closer to the lower end of its yearly range, which could suggest a value opportunity or reflect lingering bearish sentiment. The stock's 6-month change of +1.80% and YTD change of -0.03% highlight a sideways-to-slightly-positive trend, with the price currently below its 52-week high by 11.5%.
Beta
0.30
0.30x market volatility
Max Drawdown
-26.9%
Largest decline past year
52-Week Range
$240-$315
Price range past year
Annual Return
+4.4%
Cumulative gain past year
| Period | CI Return | S&P 500 |
|---|---|---|
| 1m | +0.7% | +0.3% |
| 3m | -1.4% | +4.0% |
| 6m | +1.8% | +8.3% |
| 1y | +4.4% | +20.2% |
| ytd | -0.0% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CI Fundamental Analysis
Cigna's revenue trajectory shows steady growth, with Q1 2026 revenue of $68.49 billion, up 4.57% year-over-year from $65.50 billion in Q1 2025. The multi-quarter trend reveals consistent expansion, with quarterly revenues of $67.23 billion (Q2 2025), $69.75 billion (Q3 2025), and $72.47 billion (Q4 2025), indicating a growth rate that has been stable in the mid-single digits. The Evernorth segment, which includes PBM services, is the primary revenue driver, contributing $58.44 billion in Q1 2026, while Cigna Healthcare added $11.48 billion, underscoring the company's reliance on its pharmacy business for growth. This steady, albeit moderate, growth supports the investment case for a mature healthcare company, though it lacks the acceleration seen in high-growth sectors.
Quarterly Revenue
$68.5B
2026-03
Revenue YoY Growth
+4.6%
YoY Comparison
Gross Margin
9.4%
Latest Quarter
Free Cash Flow
$7.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CI Overvalued?
Given Cigna's positive net income, the price-to-earnings (PE) ratio is the most appropriate valuation metric. The trailing PE stands at 12.34x, while the forward PE is 8.33x, indicating that the market expects significant earnings growth, as the forward multiple is 32.5% lower than the trailing multiple. This gap suggests investors are pricing in improved profitability, likely driven by the company's strategic initiatives and cost management. The PEG ratio of 0.15x further underscores that the stock is undervalued relative to its expected growth, making it an attractive value proposition.
PE
12.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 10x~17x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
8.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include Cigna's elevated debt-to-equity ratio of 0.75, which could strain cash flows if interest rates remain high, as evidenced by $357 million in quarterly interest expense. The company's thin gross margin of 9.45% leaves little room for cost pressures, and its reliance on the Evernorth PBM segment for 85% of revenue creates concentration risk. Additionally, the payout ratio of 27% is low, but any dividend cut would signal distress, though current free cash flow of $7.66 billion provides a cushion.
FAQ
The key risks include execution risk from the strategic review of eviCore and the exit from the individual exchange market, which could disrupt operations. Financial risk stems from a debt-to-equity ratio of 0.75, which could strain cash flows if interest rates rise. Competitive risk is high in the PBM industry, with thin gross margins of 9.45% making the company vulnerable to pricing pressures. Macro risks include healthcare regulatory changes and economic downturns affecting employer-sponsored insurance. The most severe risk is a failed strategic pivot, which could lead to a decline toward the 52-week low of $239.51, a -14% downside from the current price.
The 12-month forecast for CI is positive, with a base case probability of 50% targeting a range of $290-$340, aligning with the average analyst target of $340.92. The bull case, with a 30% probability, targets $340-$400, driven by successful execution of the strategic pivot and margin expansion. The bear case, with a 20% probability, targets $240-$290, reflecting execution failures or competitive pressures. The most likely scenario is the base case, assuming the company maintains steady growth and successfully navigates its strategic review.
Cigna is undervalued based on its forward P/E of 8.33x, which is a 32.5% discount to its trailing P/E of 12.34x, indicating the market expects significant earnings growth. The PEG ratio of 0.15x is exceptionally low, suggesting the stock is trading at a deep discount to its growth potential. Compared to peers in the managed healthcare sector, Cigna's valuation is at a substantial discount, reflecting concerns about its strategic direction. The market is pricing in a pessimistic scenario, but if the company delivers on its raised guidance, the stock could re-rate higher.
Cigna is a good buy for value investors given its forward P/E of 8.33x and PEG of 0.15, which are significantly below market averages. The average analyst target of $340.92 implies a 22.2% upside, and the stock offers a 2.2% dividend yield. However, the biggest downside risk is execution failure in the strategic review, which could lead to a decline toward the 52-week low of $239.51. For investors with a 12-month horizon and tolerance for moderate risk, CI is an attractive opportunity, but it requires monitoring of the strategic pivot.
Cigna is suitable for long-term investment, given its stable revenue growth, strong free cash flow, and attractive valuation. The stock's beta is not provided, but its 1-year relative strength of -13.8% indicates lower volatility than the market, making it a defensive holding. The dividend yield of 2.2% provides income, and the low payout ratio suggests potential for dividend growth. For short-term traders, the stock's sideways trend and wide analyst target range offer limited opportunities. A minimum holding period of 3-5 years is recommended to allow the strategic pivot to play out and the market to recognize the value.